Alzheimer’s disease (AD) is the main cause of dementia in the world and its etiology is not yet fully understood. The pathology of AD is primarily characterized by intracellular neurofibrillary tangles and extracellular amyloid-β plaques. Unfortunately, few treatment options are available, and most treat symptoms, as is the case of acetylcholinesterase inhibitors (IAChE) and N-methyl-d-aspartate receptor antagonists. For more than 20 years pharmaceutical research has targeted the “amyloid cascade hypothesis,” but this has not produced meaningful results, leading researchers to focus now on other characteristics of the disease and on multitarget approaches. This review aims to evaluate some new treatments that are being developed and studied. Among these are new treatments based on peptides, which have high selectivity and low toxicity; however, these compounds have a short half-life and encounter challenges when crossing the blood-brain barrier. The present review discusses up-and-coming peptides tested as treatments and explores some nanotechnological strategies to overcome the downsides. These compounds are promising, as they not only act on the symptoms but also aim to prevent progressive neuronal loss.
AloisiABarcaARomanoAGuerrieriSStorelliCRinaldiR, and others. 2013. Anti-aggregating effect of the naturally occurring dipeptide carnosine on Aβ1-42 fibril formation. PLoS One8(7):e68159. doi:10.1371/journal.pone.0068159
2.
AlyautdinRKhalinINafeezaMIHaronMHKuznetsovD.2014. Nanoscale drug delivery systems and the blood-brain barrier. Int J Nanomed9:795–811.
3.
Alzheimer’s Association. 2018. Alzheimer’s disease facts and figures. Alzheimers Dement14(3):367–429.
4.
Ashur-FabianOSegal-RuderYSkutelskyEBrenneman DE SteingartRAGiladiE, and others. 2003. The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide. Peptides24:1413–23.
5.
BansalAKirschnerMZuLCaiDZhangL.2019. Coconut oil decreases expression of amyloid precursor protein (APP) and secretion of amyloid peptides through inhibition of ADP-ribosylation factor 1 (ARF1). Brain Res1704:78–84.
6.
BarchetTMAmijiMM. 2009. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases. Expert Opin Drug Deliv6(3): 211–25.
7.
BatemanRJSiemersERMawuenyegaKGWenGBrowningKRSigurdsonWC, and others. 2009. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol66(1):48–54.
8.
BickerJAlvesGFortunaAFalcãoA.2014. Blood-brain barrier models and their relevance for a successful development of CNS drug delivery systems: a review. Eur J Pharm Biopharm87:409–32. doi:10.1016/j.ejpb.2014.03.012
9.
BuscheMAWegmannSDujardinSComminsCSchiantarelliJKlicksteinN, and others. 2019. Tau impairs neural circuits, dominating amyloid-β effects, in Alzheimer models in vivo. Nat Neurosci22:57–64. doi:10.1038/s41593-018-0289-8
10.
CastellaniRJPerryG.2019. Tau biology, tauopathy, traumatic brain injury, and diagnostic challenges. J Alzheimer’s Dis67:447–67.
ChongFPNgKYKohRYChyeSM. 2018. Tau proteins and tauopathies in Alzheimer’s disease. Cell Mol Neurobiol38:965–80. doi:10.1007/s10571-017-0574-1
16.
CounilHKranticS.2020. Synaptic activity and (neuro)inflammation in Alzheimer’s disease: could exosomes be an additional link?J Alzheimers Dis74:1029–43.
CummingsJLTongGBallardC.2019. Treatment combinations for Alzheimer’s disease: current and future pharmacotherapy options. J Alzheimers Dis67:779–94. doi:10.3233/JAD-180766
19.
DongYKataokaKTokutomiYNakoHNakamuraTToyamaK, and others. 2011. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer’s disease. FASEB J25:2911–20.
20.
dos Santos TramontinNda SilvaSArrudaRUgioniKSCanteiroPBde Bem SilveiraG, and others. 2020. Gold nanoparticles treatment reverses brain damage in Alzheimer’s disease model. Mol Neurobiol57:926–36. doi:10.1007/s12035-019-01780-w
21.
DuaTSeeherKMSivananthanSChowdharyNPotAMSaxenaS.2017. World Health Organization’s Global Action Plan on the public health response to dementia 2017-2025. Alzheimers Dement. 13:P1450–1. doi:10.1016/j.jalz.2017.07.758
22.
DumurgierJTzourioC.2020. Epidemiology of neurological diseases in older adults. Rev Neurol (Paris)176:642–8. doi:10.1016/j.neurol.2020.01.356
23.
El GaamouchFAudrainMLinWJBeckmannNJiangCHariharanS, and others. 2020. VGF-derived peptide TLQP-21 modulates microglial function through C3aR1 signaling pathways and reduces neuropathology in 5xFAD mice. Mol Neurodegener15(1):4.
24.
El-SherbinyIMEl-BazNMYacoubMH. 2015. Inhaled nano- and microparticles for drug delivery. Glob Cardiol Sci Pract2015:2.
25.
FaivreEHölscherC.2013a. D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer’s disease mouse model. J Alzheimers Dis35:267–83.
26.
FaivreEHölscherC.2013b. Neuroprotective effects of D-Al2GIP on Alzheimer’s disease biomarkers in an APP/PS1 mouse model. Alzheimers Res Ther5(2):20.
27.
FerreroJWilliamsLStellaHLeitermannKMikulskisAO’GormanJ, and others. 2016. First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer’s disease. Alzheimers Dement Transl Res Clin Interv2:169–76. doi:10.1016/j.trci.2016.06.002
28.
FolchJEttchetoMPetrovDAbadSPedrósIMarinM, and others. 2018. Review of the advances in treatment for Alzheimer disease: strategies for combating β-amyloid protein. Neurologia33(1):47–58. doi:10.1016/j.nrleng.2015.03.019
29.
ForlenzaOV. 2005. Tratamento farmacológico da doença de Alzheimer. Arch Clin Psychiatry (São Paulo)32:137–48.
30.
FranciosoAPunziPBoffiALoriCMartireSGiordanoC, and others. 2015. β-Sheet interfering molecules acting against β-amyloid aggregation and fibrillogenesis. Bioorganic Med Chem23:1671–83. doi:10.1016/j.bmc.2015.02.041
31.
FunkeSAWillboldD.2012. Peptides for therapy and diagnosis of Alzheimer’s disease. Curr Pharm Des18:755–67.
GaoCChuXGongWZhengJXieXWangY, and others. 2020a. Neuron tau-targeting biomimetic nanoparticles for curcumin delivery to delay progression of Alzheimer’s disease. J Nanobiotechnology18:71. doi:10.1186/s12951-020-00626-1
34.
GaoCWangYSunJHanYGongWLiY, and others. 2020b. Neuronal mitochondria-targeted delivery of curcumin by biomimetic engineered nanosystems in Alzheimer’s disease mice. Acta Biomater108:285–99.
35.
GaoYTanLYuJ-TTanL.2018. Tau in Alzheimer’s disease: mechanisms and therapeutic strategies. Curr Alzheimer Res15:283–300.
36.
GlatMSkaatHMenkes-CaspiNMargelSSternEA. 2013. Age-dependent effects of microglial inhibition in vivo on Alzheimer’s disease neuropathology using bioactive-conjugated iron oxide nanoparticles. J Nanobiotechnology11:32.
37.
GraulichALamyCAllevaLDillySChavattePWoutersJ, and others. 2008. Bis-tetrahydroisoquinoline derivatives: AG525E1, a new step in the search for non-quaternary non-peptidic small conductance Ca2+-activated K+ channel blockers. Bioorganic Med Chem Lett18:3440–5.
38.
GuoTNobleWHangerDP. 2017. Roles of tau protein in health and disease. Acta Neuropathol133:665–704.
39.
HampelHVassarRDe StrooperBHardyJWillemMSinghN, and others. 2020. The β-secretase BACE1 in Alzheimer’s disease. Biol Psychiatry89(8):P745–56. doi:10.1016/j.biopsych.2020.02.001
40.
HandattuSPGarberDWMonroeCEvan GroenTKadishINayyarG, and others. 2009. Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer’s disease. Neurobiol Dis34:525–34. doi:10.1016/j.nbd.2009.03.007
41.
HassanNCorderoMLSierpeRAlmadaMJuárezJValdezM, and others. 2018. Peptide functionalized magneto-plasmonic nanoparticles obtained by microfluidics for inhibition of β-amyloid aggregation. J Mater Chem B6:5091–9.
42.
HerculanoBTamuraMOhbaAShimataniMKutsunaNHisatsuneT.2013. β-Alanyl-l-histidine rescues cognitive deficits caused by feeding a high fat diet in a transgenic mouse model of Alzheimer’s disease. J Alzheimers Dis33:983–97.
43.
HerringWJCeesayPSnyderEBliwiseDBuddKHutzelmannJ, and others. 2020. Polysomnographic assessment of suvorexant in patients with probable Alzheimer’s disease dementia and insomnia: a randomized trial. Alzheimers Dement16:541–51.
44.
HockCKonietzkoUStrefferJRTracyJSignorellAMüller-TillmannsB, and others. 2003. Antibodies against β-amyloid slow cognitive decline in Alzheimers disease. Neuron38:547–54.
45.
HölscherC. 2014. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer’s disease. Alzheimers Dement. 10(1 Suppl):S47–54.
46.
HowardRMcShaneRLindesayJRitchieCBaldwinABarberR, and others. 2012. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med366:893–903. doi:10.1056/NEJMoa1106668
47.
Husna IbrahimNYahayaMFMohamedWTeohSLHuiCKKumarJ.2020. Pharmacotherapy of Alzheimer’s disease: seeking clarity in a time of uncertainty. Front Pharmacol11:261. doi:10.3389/fphar.2020.00261
48.
IqbalKDelCAlonsoAChenSChohanMOEl-AkkadEGongCX, and others. 2005. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta Mol Basis Dis1739:198–210.
49.
IqbalKLiuFGongCX. 2018. Recent developments with tau-based drug discovery. Expert Opin Drug Discov13:399–410. doi:10.1080/17460441.2018.1445084
50.
JonJPanekDMalawskaB.2016. Pharmacological Reports Therapeutic strategies for Alzheimer’s disease in clinical trials. 68:127–138. DOI: 10.1016/j.pharep.2015.07.006
51.
KalitaPRoyPKChakrabortyRSenSAhmedABDeviCM. 2018. Historical development, preparation, characterization, and pharmacokinetics of nanoparticles: a review. 2018:8–11.
52.
KarimiMEslamiMSahandi-ZangabadPMirabFFarajisafilooNShafaeiZ, and others. 2016. pH-sensitive stimulus-responsive nanocarriers for targeted delivery of therapeutic agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol8:696–716.
53.
KaurANigamKSrivastavaSTyagiADangS.2020. Memantine nanoemulsion: a new approach to treat Alzheimer’s disease. J Microencapsul37:355–65. doi:10.1080/02652048.2020.1756971
54.
KempurajDMentorSThangavelRAhmedMESelvakumarGPRaikwarSP, and others. 2019. Mast cells in stress, pain, blood-brain barrier, neuroinflammation and Alzheimer’s disease. Front Cell Neurosci13:54.
55.
KennedyMEStamfordAWChenXCoxKCummingJNDockendorfMF, and others. 2016. The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients. Sci Transl Med8(363):363ra150. doi:10.1126/scitranslmed.aad9704
56.
LauJLDunnMK. 2018. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorganic Med Chem26:2700–7. doi:10.1016/j.bmc.2017.06.052
57.
LaurentCBuéeLBlumD.2018. Tau and neuroinflammation: What impact for Alzheimer’s disease and tauopathies?Biomed J41:21–33.
58.
LozuponeMSolfrizziVD’UrsoFDi GioiaISardoneRDibelloV, and others. 2020. Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs. Expert Opin Emerg Drugs25(3):319–35. doi:10.1080/14728214.2020.1808621
59.
LyrosERagoschke-SchummAKostopoulosPSehrABackensMKalampokiniS, and others. 2020. Normal brain aging and Alzheimer’s disease are associated with lower cerebral pH: an in vivo histidine 1H-MR spectroscopy study. Neurobiol Aging87:60–9. doi:10.1016/j.neurobiolaging.2019.11.012
60.
MachadoAPRCarvalhoIOda Rocha SobrinhoHM. 2020. Neuroinflamação Na Doença De Alzheimer. Rev Bras Mil Ciências6.
61.
MaskeryMGouldingEMGenglerSMelchiorsenJURosenkildeMMHölscherC.2020. The dual GLP-1/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP/PS1 mouse model of Alzheimer’s disease. Am J Alzheimers Dis Other Demen35:1533317520953041. doi:10.1177/1533317520953041
62.
MaurerKVolkSGerbaldoH.1997. Auguste D and Alzheimer’s disease. Lancet349:1546–9. doi:10.1016/S0140-6736(96)10203-8
63.
MinLJKobayashiYMogiMTsukudaKYamadaAYamauchiK, and others. 2017. Administration of bovine casein-derived peptide prevents cognitive decline in Alzheimer disease model mice. PLoS One12(2):e0171515.
64.
MisraAGaneshSShahiwalaAShahSP. 2003. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci6:252–73.
65.
MourreCFournierCSoumireu-MouratB.1997. Apamin, a blocker of the calcium-activated potassium channel, induces neurodegeneration of Purkinje cells exclusively. Brain Res778:405–8.
66.
MudshingeSRDeoreABPatilSBhalgatCM. 2011. Nanoparticles: emerging carriers for drug delivery. Saudi Pharm J19:129–41. doi:10.1016/j.jsps.2011.04.001
67.
NovakPZilkaNZilkovaMKovacechBSkrabanaROndrusM, and others. 2019. AADvac1, an active immunotherapy for Alzheimer’s disease and non Alzheimer tauopathies: an overview of preclinical and clinical development. J Prev Alzheimers Dis6:63–9.
68.
NuydensRDispersynGDe JongMVan Den KieboomGBorgersMGeertsH.1997. Aberrant tau phosphorylation and neurite retraction during NGF deprivation in PC12 cells. Biochem Biophys Res Commun240:687–91.
69.
Ordóñez-GutiérrezLWandosellF.2020. Nanoliposomes as a therapeutic tool for Alzheimers disease. Front Synaptic Neurosci12:20.
70.
PajouheshHLenzGR. 2005. Medicinal chemical properties of successful central nervous system drugs. NeuroRx2(4):541–53.
71.
PanagakiTGenglerSHölscherC.2018. The novel DA-CH3 dual incretin restores endoplasmic reticulum stress and autophagy impairments to attenuate Alzheimer-like pathology and cognitive decrements in the APPSWE/PS1ΔE9 mouse model. J Alzheimers Dis66:195–218.
72.
PardridgeWM. 2005. The blood-brain barrier: bottleneck in brain drug development. NeuroRx2(1):3–14.
73.
Paredes-RosanCAValenciaDEBarazorda-CcahuanaHLAguilar-PinedaJAGómezB.2020. Amyloid beta oligomers: how pH influences over trimer and pentamer structures?J Mol Model26(1):1.
74.
ParkHOhJShimGChoBChangYKimS, and others. 2019. In vivo neuronal gene editing via CRISPR–Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer’s disease. Nat Neurosci22:524–8. doi:10.1038/s41593-019-0352-0
75.
PavanBDalpiazACilibertiNBiondiCManfrediniSVertuaniS.2008. Progress in drug delivery to the central nervous system by the prodrug approach. Molecules13:1035–65.
76.
PinheiroRGRGranjaALoureiroJAPereiraMCPinheiroMNevesAR, and others. 2020. Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer’s disease. Eur J Pharm Sci148:105314. doi:10.1016/j.ejps.2020.105314
77.
PortronAJordanPDraperKMuenzerCDickersonDvan IerselT, and others. 2020. A phase I study to assess the effect of speed of injection on pain, tolerability, and pharmacokinetics after high-volume subcutaneous administration of gantenerumab in healthy volunteers. Clin Ther42:108–120.e1.
78.
PradeepkiranJAReddyAPReddyPH. 2019. Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer’s disease. Drug Discov Today24:616–23. doi:10.1016/j.drudis.2018.11.005
PriceJLMorrisJC. 1999. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol45(3):358–68.
81.
PrickaertsJVan GoethemNPChesworthRShapiroGBoessFGMethfesselC, and others. 2012. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology62:1099–110. doi:10.1016/j.neuropharm.2011.10.024
82.
QiuCKivipeltoMVon StraussE.2009. Epidemiology of Alzheimer’s disease: Occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci11:111–28.
83.
QuerfurthHWLaFerlaFM. 2010. Alzheimer’s disease. N Engl J Med362(4):329–44. doi:10.1056/NEJMra0909142
84.
RaiMYadavAIngleAPReshetilovABlanco-PrietoMJFeitosaCM. 2019. Neurodegenerative diseases: the real problem and nanobiotechnological solutions. In: RaiMYadavA, editors. Nanobiotechnology in neurodegenerative diseases. Springer. pp 1–17.
85.
RibaričS. 2018. Peptides as potential therapeutics for Alzheimer’s disease. Molecules23(2):283.
86.
RoyERZhengHCaoW.2020. Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. Graphical abstract. J Clin Invest130:1912–30.
87.
SanchisISpinelliRAschemacherNHumpolaMVSianoA.2020. Acetylcholinesterase inhibitory activity of a naturally occurring peptide isolated from Boana pulchella (Anura: Hylidae) and its analogs. Amino Acids52:387–96. doi:10.1007/s00726-019-02815-1
88.
SeifanASchelkeMObeng-AduasareYIsaacsonR.2015. Early life epidemiology of Alzheimer’s disease—a critical review. Neuroepidemiology45:237–54.
89.
SevignyJChiaoPBussièreTWeinrebPHWilliamsLMaierM, and others. 2016. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature537:50–6. doi:10.1038/nature19323
90.
ShiLZhangZLiLHölscherC.2017. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model. Behav Brain Res. 327:65–74. doi:10.1016/j.bbr.2017.03.032
91.
SilmanISussmanJL. 2005. Acetylcholinesterase: “classical” and “non-classical” functions and pharmacology. Curr Opin Pharmacol5:293–302.
92.
SinghRLillardJW. 2009. Nanoparticle-based targeted drug delivery. Exp Mol Pathol86:215–23. doi:10.1016/j.yexmp.2008.12.004
SöllvanderSNikitidouEBrolinRSöderbergLSehlinDLannfeltL, and others. 2016. Accumulation of amyloid-β by astrocytes result in enlarged endosomes and microvesicle-induced apoptosis of neurons. Mol Neurodegener11(1):38.
95.
StelzmannRANorman SchnitzleinHReed MurtaghF.1995. An English translation of Alzheimer’s 1907 paper, “Über Eine Eigenartige Erkankung der Hirnrinde.”Clin Anat8(6):429–31. doi:10.1002/ca.980080612
96.
SuYChangPT. 2001. Acidic pH promotes the formation of toxic fibrils from β-amyloid peptide. Brain Res893:287–91.
97.
TangMTaghibiglouC.2017. The mechanisms of action of CUR in Alzheimer’s disease. J Alzheimers Dis58(4):1003–6.
WangADasPSwitzerRCGoldeTEJankowskyJL. 2011. Robust amyloid clearance in a mouse model of Alzheimer’s disease provides novel insights into the mechanism of amyloid-β immunotherapy. J Neurosci31:4124–36.
102.
WangHZhangH.2019. Reconsideration of anticholinesterase therapeutic strategies against Alzheimer’s disease. ACS Chem Neurosci10:852–62.
103.
WenMMEl-SalamouniNSEl-RefaieWMHazzahHAAliMMTosiG, and others. 2017. Nanotechnology-based drug delivery systems for Alzheimer’s disease management: technical, industrial, and clinical challenges. J Control Release245:95–107. doi:10.1016/j.jconrel.2016.11.025
104.
WilsonBSamantaMKSanthiKKumarKPSParamakrishnanNSureshB.2008a. Poly(n-butyl cyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s disease. Brain Res1200:159–68.
105.
WilsonBSamantaMKSanthiKKumarKPSParamakrishnanNSureshB.2008b. Targeted delivery of tacrine into the brain with polysorbate 80–coated poly(n-butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm70:75–84.
106.
YaminGRuchalaPTeplowDB. 2009. A peptide hairpin inhibitor of amyloid β-protein oligomerization and fibrillogenesis. Biochemistry48:11329–31.
107.
YeMChungHSLeeCYoonMSYuARKimJS, and others. 2016. Neuroprotective effects of bee venom phospholipase A2 in the 3xTg AD mouse model of Alzheimer’s disease. J Neuroinflammation13:10. doi:10.1186/s12974-016-0476-z
108.
YeXFengTTammineniPChangQJeongYYMargolisDJ, and others. 2017. Regulation of synaptic amyloid-β generation through BACE1 retrograde transport in a mouse model of Alzheimer’s disease. J Neurosci37:2639–55.
109.
ZhangHHaoCQuASunMXuLXuC, and others. 2020. Light-induced chiral iron copper selenide nanoparticles prevent β-amyloidopathy in vivo. Angew Chem Int Ed Engl59(18):7131–8.
110.
ZhangZHXiGMLiWCLingHYQuPFangX Bin. 2010. Cyclic-AMP response element binding protein and tau are involved in the neuroprotective mechanisms of nerve growth factor during focal cerebral ischemia/reperfusion in rats. J Clin Neurosci17:353–6. doi:10.1016/j.jocn.2009.07.086
111.
ZhangZQHölscherC.2020. GIP has neuroprotective effects in Alzheimer and Parkinson’s disease models. Peptides125:170184. doi:10.1016/j.peptides.2019.170184.
112.
ZhouHGongYLiuYHuangAZhuXLiu Jiawei, and others. 2020. Intelligently thermoresponsive flower-like hollow nano-ruthenium system for sustained release of nerve growth factor to inhibit hyperphosphorylation of tau and neuronal damage for the treatment of Alzheimer’s disease. Biomaterials237:119822. doi:10.1016/j.biomaterials.2020.119822.
